The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients
- 70 Downloads
To explore the efficacy and patterns of treatment failure of radical radiotherapy in newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients.
We included 39 newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients who received radical radiotherapy and chemotherapy in Zhejiang Cancer Hospital. Treatment and prognosis information were collected. The Kaplan–Meier methods and Cox proportional hazards models were used to calculate survival rates and analyze prognostic factors.
After a median follow-up time of 38 months, the 1-, 3-, and 5-year overall survival rates were 97, 70, and 57.9%, while the 1-, 3-, and 5-year progression-free survival rates were 87, 59, and 50.9%, respectively. Age, numbers of metastases lesions, cycles, and schemes of chemotherapy were independent prognostic factors of the overall survival. Patients with no more than three metastasis lesions had a higher survival rate than those with ≥ 3 metastatic lesions (P = 0.023). More than four cycles chemotherapy provide a higher survival rate than less than four cycles. Chemotherapy including docetaxel had a significantly survival advantages (P = 0.041).
Radical radiotherapy is important for newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients, which can still achieve long-term survival after chemo-radiotherapy.
KeywordsNasopharyngeal neoplasms Radiotherapy Oligo-metastases Prognosis
We would like to thank all patients, GPs, and nurses for their participation.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
Research involving human participants
The study was carried out according to the precepts of the Helsinki Declaration. The study protocol was reviewed by the Medical Ethics Committee of the Zhejiang Cancer Hospital and they concluded that approval by a Medical Ethics Committee was not obligatory for this study.
All participants provided written informed consent.
- 12.Wang CL, Su SF, Ouyang WW, et al. Significance of three dimensional radical radiotherapy dose determined by organ-lesion combination for primary tumor of oligometastatic stage IV NSCLC: a reanalysis of PPRA-RTOG 003. Chin J Radiat Oncol. 2016;25(6):576–81.Google Scholar
- 13.Lan YH, Tian YM, Bai L, et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma. Chin J Radiat Oncol. 2015;4:421–6.Google Scholar
- 17.Jiang R, You R, Pei X, et al. Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients’ survival. Oncotarget. 2016;7(3):3645.CrossRefGoogle Scholar
- 20.Li W, Bai Y, Wu M, et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: propensity score matching analysis. Oncotarget. 2016;8:52132.Google Scholar